세계의 출혈성 질환 치료 시장 보고서(2025년)

Bleeding disorders constitute a category of medical conditions characterized by inadequate blood clotting, leading to prolonged bleeding following surgery, injury, menstruation, or trauma. The management of these disorders aims to either arrest or diminish the frequency of bleeding episodes.

Key modalities in the treatment of bleeding disorders encompass desmopressin (DDAVP), hormone replacement therapy, contraceptives, anti-fibrinolytic or clot-stabilizing medications, fibrin sealants, drugs for topical application on cuts, and pipeline analysis. Desmopressin (DDAVP) therapies play a pivotal role in diagnosing individuals with mild hemophilia A or von Willebrand disease, effectively halting bleeding. Targeted diseases include hemophilia A, hemophilia B, von Willebrand disease, liver disease, and others. These interventions cater to diverse end users, including hospitals, clinics, specialty clinics, research institutes, and related entities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The bleeding disorders treatment market research report is one of a series of new reports from The Business Research Company that provides Bleeding disorders treatment market statistics, including bleeding disorders treatment industry global market size, regional shares, competitors with bleeding disorders treatment market share, detailed Bleeding disorders treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the bleeding disorders treatment industry. This bleeding disorders treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The bleeding disorders treatment market size has grown strongly in recent years. It will grow from $16.95 billion in 2024 to $18.45 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to increased patient awareness, access to healthcare, advancements in hemophilia therapies, global market expansion.

The bleeding disorders treatment market size is expected to see strong growth in the next few years. It will grow to $25.93 billion in 2029 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to aging population, personalized medicine, patient advocacy and support, rise in disposable income, rise in healthcare expenditure. Major trends in the forecast period include personalized treatment plans, expansion of telehealth services, advanced clotting factor therapies, rna-based treatments, access to orphan drug designation.

The forecast of 8.9% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. hemophilia care by inflating prices of recombinant clotting factors and gene therapy vectors developed in Ireland and Belgium, resulting in treatment gaps and higher specialty pharmacy expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growth of the bleeding disorders treatment market is anticipated to be propelled by the increasing number of diagnosed hemophilia patients. Hemophilia, an inherited bleeding disorder characterized by inadequate blood clotting, necessitates replacement therapy for treatment. This involves replacing the deficient blood clotting factors with human plasma concentrates or recombinant forms of clotting factors VIII or IX. In 2021, the World Federation of Hemophilia reported nearly 234,000 confirmed cases of hemophilia worldwide. The escalating number of diagnosed hemophilia patients is a significant driver behind the growth of the bleeding disorders treatment market, emphasizing the importance of advancing treatments for this inherited disorder.

The increasing healthcare expenditure is expected to fuel the growth of the bleeding disorders treatment market in the coming years. Healthcare expenditure refers to the total spending on healthcare costs, encompassing all money allocated to healthcare-related goods and services within a specific healthcare system or economy. This expenditure is vital for supporting the development and accessibility of treatments for bleeding disorders. For example, in October 2024, the Centers for Medicare & Medicaid Services, a US-based federal agency, reported that the health spending share of GDP rose from 17.3 percent in 2022 to 19.7 percent in 2032. Thus, the rise in healthcare expenditure is driving the expansion of the bleeding disorders treatment market.

Major companies in the bleeding disorder treatment market are concentrating on the development of innovative technologies, such as single-dose treatments, to improve treatment efficacy and enhance patient quality of life by reducing the necessity for ongoing therapies. Single-dose treatment refers to a therapeutic strategy that provides a complete treatment with a single administration, aiming for long-lasting effects without the requirement for multiple doses. For example, in June 2023, BioMarin Pharmaceutical Inc., a US-based biotechnology firm, introduced BioMarin's ROCTAVIANTM (valoctocogene roxaparvovec-rvox). ROCTAVIAN is specifically designed for adults with severe hemophilia A (characterized by FVIII activity levels below 1 IU/dL) who do not have pre-existing antibodies to adeno-associated virus serotype 5 (AAV5) as confirmed by an FDA-approved test.

Leading companies in the bleeding disorder treatment market are actively developing on-demand treatments to control bleeding episodes and perioperative management solutions, addressing a broader customer base and aiming to boost sales and revenue. On-demand treatment is a crucial aspect of managing bleeding disorders, empowering individuals to respond promptly to bleeding episodes and ensuring safe perioperative care during surgical procedures. Ongoing advances in clotting factor therapies and treatment strategies are enhancing the overall quality of life for individuals with bleeding disorders, enabling them to lead more active and fulfilling lives. In February 2023, the collaboration between Sanofi and Sobi resulted in the development of the first-in-class, high-sustained factor VIII replacement therapy known as ALTUVIIIO, which received U.S. FDA approval. This groundbreaking medication offers a unique once-a-week dosing schedule, producing factor activity levels above 40% for the majority of the week and significantly reducing bleeding compared to previous factor VIII prophylaxis.

In October 2022, Pfizer Inc., a prominent U.S.-based pharmaceutical and biotechnology corporation, made a strategic move by acquiring Global Blood Therapeutics, Inc. (GBT) for an undisclosed amount. This acquisition was geared towards leveraging GBT's portfolio to expedite discovery processes and provide a range of potential best-in-class medicines for patients with sickle cell disease. Global Blood Therapeutics, Inc., a U.S.-based biopharmaceutical company specializing in the treatment of blood disorders, contributed valuable expertise and products to Pfizer's portfolio, aligning with the broader industry trend of strategic acquisitions to strengthen capabilities and enhance the range of therapeutic offerings in the bleeding disorder treatment market.

Major companies operating in the bleeding disorders treatment market include AbbVie Inc., Bayer AG, Novo Nordisk A/S, Pfizer Inc., Biogen Inc., CSL Behring Company, Grifols SA, Octapharma AG, BDI Pharma Inc., Ferring Pharmaceuticals Ltd., Xenetic Biosciences Inc., Sanofi SA, Alnylam Pharmaceuticals Inc., Novartis AG, Shire plc, Novo Nordisk, Grifols SA, F. Hoffmann-La Roche AG, Sanofi Corporation, Takeda Pharmaceutical Company Limited, Kedrion S.p.A, Biotest AG, LFB S.A, Emergent BioSolutions Inc., Bio Products Laboratory Ltd., HEMA Biologics LLC, ADMA Biologics Inc., Grifols Biologicals Inc., Octapharma Plasma Inc., Kedrion Biopharma Inc., BPL Plasma Inc., BioLife Plasma Services, CSL Plasma Ltd., Grifols Shared Services North America Inc., Octapharma USA Inc., Shire US Inc., Pfizer Canada Inc., Grifols Canada Ltd., Octapharma Canada Inc.

North America was the largest region in the bleeding disorders treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bleeding disorders treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the bleeding disorders treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The bleeding disorders treatment market includes revenues earned by entities by recombinant coagulation factor concentrates, plasma-derived coagulation factor concentrates. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Bleeding Disorders Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on bleeding disorders treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for bleeding disorders treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The bleeding disorders treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Desmopressin (DDAVP); Hormone Replacement Therapy; Contraceptives; Anti-Fibrinolytic or Clot-Stabilizing Drugs; Fibrin Sealants; Drugs Applied To Cuts; Pipeline Analysis
• 2) By Disease Type: Hemophilia A; Hemophilia B; Von Willebrand disease; Liver disease; Other Disease Types
• 3) By End User: Hospitals; Clinics; Specialty Clinics; Research Institutes; Other End Users
• Subsegments:
• 1) By Desmopressin (DDAVP): Intravenous Formulations; Nasal Spray Formulations
• 2) By Hormone Replacement Therapy: Estrogen Therapy; Progesterone Therapy
• 3) By Contraceptives: Combined Oral Contraceptives; Progestin-Only Contraceptives
• 4) By Anti-Fibrinolytic or Clot-Stabilizing Drugs: Tranexamic Acid; Aminocaproic Acid
• 5) By Fibrin Sealants: Tisseel; Artiss
• 6) By Drugs Applied To Cuts: Antiseptics; Topical Hemostatic Agents
• 7) By Pipeline Analysis: Upcoming Treatments in Development; Novel Therapeutics and Technologies
• Companies Mentioned: AbbVie Inc.; Bayer AG; Novo Nordisk A/S; Pfizer Inc.; Biogen Inc.; CSL Behring Company; Grifols SA; Octapharma AG; BDI Pharma Inc.; Ferring Pharmaceuticals Ltd.; Xenetic Biosciences Inc.; Sanofi SA; Alnylam Pharmaceuticals Inc.; Novartis AG; Shire plc; Novo Nordisk; Grifols SA; F. Hoffmann-La Roche AG; Sanofi Corporation; Takeda Pharmaceutical Company Limited; Kedrion S.p.A; Biotest AG; LFB S.A; Emergent BioSolutions Inc.; Bio Products Laboratory Ltd.; HEMA Biologics LLC; ADMA Biologics Inc.; Grifols Biologicals Inc.; Octapharma Plasma Inc.; Kedrion Biopharma Inc.; BPL Plasma Inc.; BioLife Plasma Services; CSL Plasma Ltd.; Grifols Shared Services North America Inc.; Octapharma USA Inc.; Shire US Inc.; Pfizer Canada Inc.; Grifols Canada Ltd.; Octapharma Canada Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Bleeding Disorders Treatment Market Characteristics

3. Bleeding Disorders Treatment Market Trends And Strategies

4. Bleeding Disorders Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Bleeding Disorders Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Bleeding Disorders Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Bleeding Disorders Treatment Market Growth Rate Analysis
• 5.4. Global Bleeding Disorders Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Bleeding Disorders Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Bleeding Disorders Treatment Total Addressable Market (TAM)

6. Bleeding Disorders Treatment Market Segmentation

• 6.1. Global Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Desmopressin (DDAVP)
• Hormone Replacement Therapy
• Contraceptives
• Anti-Fibrinolytic or Clot-Stabilizing Drugs
• Fibrin Sealants
• Drugs Applied to Cuts
• Pipeline Analysis
• 6.2. Global Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hemophilia A
• Hemophilia B
• Von Willebrand Disease
• Liver Disease
• Other Disease Types
• 6.3. Global Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Specialty Clinics
• Research Institutes
• Other End Users
• 6.4. Global Bleeding Disorders Treatment Market, Sub-Segmentation Of Desmopressin (DDAVP), By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous Formulations
• Nasal Spray Formulations
• 6.5. Global Bleeding Disorders Treatment Market, Sub-Segmentation Of Hormone Replacement Therapy, By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Estrogen Therapy
• Progesterone Therapy
• 6.6. Global Bleeding Disorders Treatment Market, Sub-Segmentation Of Contraceptives, By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Combined Oral Contraceptives
• Progestin-Only Contraceptives
• 6.7. Global Bleeding Disorders Treatment Market, Sub-Segmentation Of Anti-Fibrinolytic or Clot-Stabilizing Drugs, By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tranexamic Acid
• Aminocaproic Acid
• 6.8. Global Bleeding Disorders Treatment Market, Sub-Segmentation Of Fibrin Sealants, By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tisseel
• Artiss
• 6.9. Global Bleeding Disorders Treatment Market, Sub-Segmentation Of Drugs Applied To Cuts, By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antiseptics
• Topical Hemostatic Agents
• 6.10. Global Bleeding Disorders Treatment Market, Sub-Segmentation Of Pipeline Analysis, By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Upcoming Treatments in Development
• Novel Therapeutics and Technologies

7. Bleeding Disorders Treatment Market Regional And Country Analysis

• 7.1. Global Bleeding Disorders Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Bleeding Disorders Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Bleeding Disorders Treatment Market

• 8.1. Asia-Pacific Bleeding Disorders Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Bleeding Disorders Treatment Market

• 9.1. China Bleeding Disorders Treatment Market Overview
• 9.2. China Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Bleeding Disorders Treatment Market

• 10.1. India Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Bleeding Disorders Treatment Market

• 11.1. Japan Bleeding Disorders Treatment Market Overview
• 11.2. Japan Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Bleeding Disorders Treatment Market

• 12.1. Australia Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Bleeding Disorders Treatment Market

• 13.1. Indonesia Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Bleeding Disorders Treatment Market

• 14.1. South Korea Bleeding Disorders Treatment Market Overview
• 14.2. South Korea Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Bleeding Disorders Treatment Market

• 15.1. Western Europe Bleeding Disorders Treatment Market Overview
• 15.2. Western Europe Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Bleeding Disorders Treatment Market

• 16.1. UK Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Bleeding Disorders Treatment Market

• 17.1. Germany Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Bleeding Disorders Treatment Market

• 18.1. France Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Bleeding Disorders Treatment Market

• 19.1. Italy Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Bleeding Disorders Treatment Market

• 20.1. Spain Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Bleeding Disorders Treatment Market

• 21.1. Eastern Europe Bleeding Disorders Treatment Market Overview
• 21.2. Eastern Europe Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Bleeding Disorders Treatment Market

• 22.1. Russia Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Bleeding Disorders Treatment Market

• 23.1. North America Bleeding Disorders Treatment Market Overview
• 23.2. North America Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Bleeding Disorders Treatment Market

• 24.1. USA Bleeding Disorders Treatment Market Overview
• 24.2. USA Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Bleeding Disorders Treatment Market

• 25.1. Canada Bleeding Disorders Treatment Market Overview
• 25.2. Canada Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Bleeding Disorders Treatment Market

• 26.1. South America Bleeding Disorders Treatment Market Overview
• 26.2. South America Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Bleeding Disorders Treatment Market

• 27.1. Brazil Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Bleeding Disorders Treatment Market

• 28.1. Middle East Bleeding Disorders Treatment Market Overview
• 28.2. Middle East Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Bleeding Disorders Treatment Market

• 29.1. Africa Bleeding Disorders Treatment Market Overview
• 29.2. Africa Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Bleeding Disorders Treatment Market Competitive Landscape And Company Profiles

• 30.1. Bleeding Disorders Treatment Market Competitive Landscape
• 30.2. Bleeding Disorders Treatment Market Company Profiles
  • 30.2.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Bleeding Disorders Treatment Market Other Major And Innovative Companies

• 31.1. CSL Behring Company
• 31.2. Grifols SA
• 31.3. Octapharma AG
• 31.4. BDI Pharma Inc.
• 31.5. Ferring Pharmaceuticals Ltd.
• 31.6. Xenetic Biosciences Inc.
• 31.7. Sanofi SA
• 31.8. Alnylam Pharmaceuticals Inc.
• 31.9. Novartis AG
• 31.10. Shire plc
• 31.11. Novo Nordisk
• 31.12. Grifols SA
• 31.13. F. Hoffmann-La Roche AG
• 31.14. Sanofi Corporation
• 31.15. Takeda Pharmaceutical Company Limited

32. Global Bleeding Disorders Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Bleeding Disorders Treatment Market

34. Recent Developments In The Bleeding Disorders Treatment Market

35. Bleeding Disorders Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Bleeding Disorders Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Bleeding Disorders Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Bleeding Disorders Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer